Literature DB >> 2218496

Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2.

R Lupu1, R Colomer, G Zugmaier, J Sarup, M Shepard, D Slamon, M E Lippman.   

Abstract

The erbB2 oncogene encodes a 185-kilodalton transmembrane protein whose sequence is similar to the epidermal growth factor receptor (EGFR). A 30-kilodalton factor (gp30) secreted from MDA-MB-231 human breast cancer cells was shown to be a ligand for p185erbB2. An antibody to EGFR abolished the tyrosine phosphorylation induced by EGF and transforming growth factor-alpha (TGF-alpha) but only partially blocked that produced by gp30 in SK-BR-3 breast cancer cells. In two cell lines that overexpress erbB2 but do not expresss EGFR (MDA-MB-453 breast cancer cells and a Chinese hamster ovary cell line that had been transfected with erbB2), phosphorylation of p185erbB2 was induced only by gp30. The gp30 specifically inhibited the growth of cells that overexpressed p185erbB2. An antibody to EGFR had no effect on the inhibition of SK-BR-3 cell colony formation obtained with gp30. Thus, it appeared that gp30 interacted directly with the EGFR and erbB2. Direct binding of gp30 to p185erbB2 was confirmed by binding competition experiments, where gp30 was found to displace the p185erbB2 binding of a specific antibody to p185erbB2. The evidence described here suggests that gp30 is a ligand for p185erbB2.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2218496     DOI: 10.1126/science.2218496

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  68 in total

1.  Complete sequence of the human mucin MUC4: a putative cell membrane-associated mucin.

Authors:  N Moniaux; S Nollet; N Porchet; P Degand; A Laine; J P Aubert
Journal:  Biochem J       Date:  1999-03-01       Impact factor: 3.857

2.  Negative autoregulation of the neu gene is mediated by a novel enhancer.

Authors:  X Y Zhao; M C Hung
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

3.  Adenovirus-directed expression of Q227L-G alpha(s) inhibits growth of established tumors of later-stage human breast cancer cells in athymic mice.

Authors:  Tara Ann Santore; Yibang Chen; Martine J Smit; Ravi Iyengar
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

4.  MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo.

Authors:  Y Liu; D el-Ashry; D Chen; I Y Ding; F G Kern
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

5.  Expression of growth factors and their receptors in human esophageal carcinomas: regulation of expression by epidermal growth factor and transforming growth factor alpha.

Authors:  K Yoshida; H Kuniyasu; W Yasui; Y Kitadai; T Toge; E Tahara
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

6.  Overview of human primary tumorgraft models: comparisons with traditional oncology preclinical models and the clinical relevance and utility of primary tumorgrafts in basic and translational oncology research.

Authors:  David H Lum; Cindy Matsen; Alana L Welm; Bryan E Welm
Journal:  Curr Protoc Pharmacol       Date:  2012-12

Review 7.  The neu-protein and breast cancer.

Authors:  C R De Potter; A M Schelfhout
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

8.  Inverse regulation of human ERBB2 and epidermal growth factor receptors by tumor necrosis factor alpha.

Authors:  H Kalthoff; C Roeder; J Gieseking; I Humburg; W Schmiegel
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

Review 9.  Molecular biology of breast carcinoma.

Authors:  D el-Ashry; M E Lippman
Journal:  World J Surg       Date:  1994 Jan-Feb       Impact factor: 3.352

10.  Expression of Her2/neu oncogene product p185 in correlation to clinicopathological and prognostic factors of gastric carcinoma.

Authors:  J Jaehne; C Urmacher; H T Thaler; H Friedlander-Klar; C Cordon-Cardo; H J Meyer
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.